ZNTL
NASDAQZentalis Pharmaceuticals Llc
$6.61
+2.19 (+49.55%)
2026-04-10 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$190.8M
P/E Ratio
N/A
52W Low
52W High
$1.21
$6.95
Volume
46.1M
Analyst Rating
Hold
Target: $5
4 Analyst Ratings
Strong Buy
0
Buy
0
Hold
4
Sell
0
Price Target Range
Low: $5
Avg: $5
High: $5
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib ...
Employees
166
Website
zentalis.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | N/A | N/A% | -$137.1M | -$125.2M |
| 2024 | $67.4M | -283.6% | -$165.8M | -$170.6M |
| 2023 | N/A | N/A% | -$292.2M | -$207.2M |
| 2022 | N/A | N/A% | -$236.8M | -$161.2M |
| 2021 | N/A | N/A% | -$158.7M | -$148.0M |
| 2025 Q4 | N/A | N/A% | -$35.2M | -$30.9M |
| 2025 Q3 | N/A | N/A% | -$26.7M | -$27.0M |
| 2025 Q2 | N/A | N/A% | -$26.9M | -$34.7M |
| 2025 Q1 | N/A | N/A% | -$48.3M | -$32.6M |
| 2024 Q4 | $26.9M | -185.6% | -$47.5M | -$39.7M |
| 2024 Q3 | N/A | N/A% | -$40.2M | -$44.0M |
| 2024 Q2 | N/A | N/A% | -$88.3M | -$35.0M |
| 2024 Q1 | $40.6M | -61.1% | $10.1M | -$51.9M |